Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20866202 | 1.00 | SRC (0.46) | SRCALDH1A1KDM4EUSP2EGFR | |
| SCHEMBL482053 | 0.95 | AR (0.42) | SRCALDH1A1KDM4EUSP2EGFR | |
| SCHEMBL15364623 | 0.91 | AR (0.45) | SRCALDH1A1KDM4EUSP2EGFR | |
| SCHEMBL15365341 | 0.91 | AR (0.45) | SRCALDH1A1KDM4EUSP2EGFR | |
| SCHEMBL15365210 | 0.91 | AR (0.45) | SRCALDH1A1KDM4EUSP2EGFR | |
| SCHEMBL2164383 | 0.86 | AR (0.46) | SRCALDH1A1KDM4EUSP2AR | |
| SCHEMBL2163172 | 0.86 | ALDH1A1 (0.41) | SRCALDH1A1KDM4EUSP2EGFR | |
| SCHEMBL17341734 | 0.86 | AR (0.46) | SRCALDH1A1KDM4EUSP2AR | |
| SCHEMBL82833 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4EUSP2EGFRAR | |
| SCHEMBL23914846 | 0.82 | AR (0.45) | SRCALDH1A1KDM4EUSP2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2005115145-A2 | QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS | WYETH (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | SRC 960/4885ALDH1A1 530/4885KDM4E 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.